Literature DB >> 10763765

Overview of new immunosuppressive therapies.

T E Nevins1.   

Abstract

This review covers the new immunosuppressive drugs that have appeared in the past 5 years. It begins with the newest formulation (Neoral, Sandoz Pharmaceuticals, East Hanover, NJ, USA) of the clinically "mature" drug cyclosporin A and then reviews the literature on tacrolimus, sirolimus, and mycophenolate mofetil. In each case, the emphasis is on the evolution of experience with the drug and on the questions that the drug poses for pediatricians considering the risk-benefit ratio of the drug in children.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10763765     DOI: 10.1097/00008480-200004000-00011

Source DB:  PubMed          Journal:  Curr Opin Pediatr        ISSN: 1040-8703            Impact factor:   2.856


  3 in total

Review 1.  Immunosuppressive potency of mechanistic target of rapamycin inhibitors in solid-organ transplantation.

Authors:  Alberto Baroja-Mazo; Beatriz Revilla-Nuin; Pablo Ramírez; José A Pons
Journal:  World J Transplant       Date:  2016-03-24

2.  A stochastic model describes the heterogeneous pharmacokinetics of cyclosporin.

Authors:  L Claret; A Iliadis; P Macheras
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-10       Impact factor: 2.745

3.  Immunosuppression in Pediatric Heart Transplantation: 2003 and Beyond.

Authors:  Subash C. Reddy; Karen Laughlin; Steven A. Webber
Journal:  Curr Treat Options Cardiovasc Med       Date:  2003-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.